AmpliPhi BioSciences Names New CEO to Lead the Fight Against Drug-Resistant Infections
![](/46/pdcnewsitem/03/44/45/jRfpWsys6TVPw4q.jpg)
AmpliPhi BioSciences Corp. has appointed Scott Salka as the new CEO. Mr. Salka will replace Interim CEO and Chairman of AmpliPhi, Jeremy Curnock Cook, effective 18 May. Mr Curnock Cook will remain in his role as Chairman.
“Mr Salka’s leadership will enable AmpliPhi to execute on its mission to develop innovative therapeutic solutions aimed at the growing problem of combating antibiotic resistant bacterial infections,” said Mr Curnock Cook. “His extensive experience in building biotech companies with a focus on technology development and discovery will accelerate the progress of our bacteriophage candidates towards the clinic, and his skill set, combined with over 25 years of experience, will further strengthen AmpliPhi’s position in this exciting field.”
Since 2010, Mr Salka has served as CEO of Aspyrian Therapeutics Inc., a company focused on developing near-infrared photoimmunotherapy (PIT) therapies. Prior to this role, he was the CEO of Ambit Biosciences (acquired by Daiichi Sankyo in 2014). During Mr Salka’s tenure at Ambit, a company developing treatments for oncology, autoimmune and inflammatory diseases, he was responsible for transforming the company from a service contract business to a fully capable drug discovery and development enterprise. Prior to joining Ambit in 2001, he served as the President and CEO of two privately held genomics companies, Arcaris, Inc. and 454 Corporation (sold to Roche in 2007). He also previously co-founded one of the first commercial genomics companies, Sequana Therapeutics, Inc., a pioneer in the effort to commercialize the international Human Genome Project.
Mr Salka will be based in San Diego in his role as CEO. He is currently a board member and professor of entrepreneurship at San Diego State University College of Business Administration, and will continue to serve as a board member of Aspyrian Therapeutics Inc. He also previously served as a director and chairman of the audit committee for Sorrento Therapeutics. Mr Salka received his MBA from Carnegie Mellon University and his BS in finance from San Diego State University.
“I am excited to have been selected as CEO of AmpliPhi at this important time in the company’s history,” noted Mr Salka. “With a strong proprietary technology platform, first-in-class cGMP manufacturing capabilities and excellent lead pipeline candidates for addressing a major global health problem, AmpliPhi is strongly positioned to bring new therapies for treating deadly bacterial infections to market. I am eager to join the executive leadership team during what will surely be a critical growth period for not only the company but also the industry.”
AmpliPhi is advancing three pre-clinical programs in methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa infections in Cystic Fibrosis and Clostridium difficile.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance